Induction of Donor Specific Tolerance in Recipients of Living Kidney Allografts by Donor FCRx Infusion

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by University of Louisville
Sponsor:
Collaborators:
Northwestern University
Regenerex, LLC
Information provided by (Responsible Party):
University of Louisville
ClinicalTrials.gov Identifier:
NCT00497926
First received: July 6, 2007
Last updated: April 21, 2014
Last verified: April 2014

July 6, 2007
April 21, 2014
March 2008
March 2025   (final data collection date for primary outcome measure)
Enriched Hematopoetic Stem Cell Engraftment [ Time Frame: One month to three years ] [ Designated as safety issue: No ]
Bone marrow engraftment/chimerism
Complete list of historical versions of study NCT00497926 on ClinicalTrials.gov Archive Site
Not Provided
Tolerance induction
Not Provided
Not Provided
 
Induction of Donor Specific Tolerance in Recipients of Living Kidney Allografts by Donor FCRx Infusion
Induction of Donor Specific Tolerance in Recipients of Living Kidney Allografts by Donor FCRx Infusion

Research study which involves the use of a combination of an Enriched Hematopoetic Stem Cell Infusion (stem cells, produced by the bone marrow, generate the cells that form the blood elements, help fight infection and assist in clotting) and kidney transplantation from the same donor to try to avoid the need for long-term anti-rejection drug therapy. The desired result of this study is to allow your body to develop "tolerance" to the transplanted kidney. Tolerance means that your body would see the transplanted kidney as part of you and not try to get rid of, or reject it. To prevent rejection, drugs called immunosuppressive agents must be taken on a daily basis. The purpose of this study is to determine if this procedure is safe and to try to substantially reduce or even eliminate the need for anti-rejection medications.

Not Provided
Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Kidney Transplantation
Biological: Kidney and hematopoietic stem cell transplant/novel platform technology
Bone marrow will be processed via a new technology which will enrich hematopoietic stem cells and graft facilitating cells. Monitoring for chimerism will be done at key time points.
Experimental: Enriched Hematopoetic Stem Cell Transplant
Intervention: Biological: Kidney and hematopoietic stem cell transplant/novel platform technology
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
30
March 2030
March 2025   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient must be between the ages of 18 and 65 years and meet the institution's criteria for renal transplantation for end-organ failure
  • Meets the transplant criteria by the study site and both the recipient and donor have been accepted as candidates for standard of care living kidney donation and transplantation
  • Patient is receiving a renal transplant only
  • The crossmatch is negative between donor and recipient. An initial crossmatch will be performed prior to stem cell mobilization to determine if subject can proceed with the pheresis.
  • Potential recipients who are women of child bearing potential must have a negative pregnancy test (urine test is acceptable) within 48 hours prior to receiving Granulocyte colony-stimulating factor (G-CSF)
  • Potential donors who are women of child bearing potential must have a negative pregnancy test (urine test is acceptable) within 48 hours prior to receiving G-CSF
  • No evidence of donor-specific antibody presently or historically
  • Panel Reactive Antibody (PRA) less than or equal to 20

Note: The subjects do not need to be local residents in order to be eligible for this trial, but must be willing to reside in the area, or within a four hour drive, for the first month of the protocol so that we can monitor them closely in the early post transplant period. As long as there is insurance or funding that will cover the cost of the transplant and any research related complications, it is not necessary for the subjects to be US citizens to participate in this trial.

Exclusion Criteria:

  • Clinically active bacterial, fungal, viral or parasitic infection
  • Pregnancy
  • Clinical or serologic evidence of viral infection which would preclude the recipient from receiving a kidney transplant or FCRx infusion
  • Previous radiation therapy at a dose which would preclude Total Body Irradiation (TBI)
  • Positive crossmatch between donor and recipient
  • Evidence for immunologic memory against donor
  • BMI >35 or <18
  • Positive serologies for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), human immunodeficiency virus (HIV)
  • Insufficient funds for the bone marrow processing costs
Both
18 Years to 65 Years
No
Contact: Joseph Leventhal, MD 312-695-9019 jleventh@nmh.org
United States
 
NCT00497926
ICT-13947-120209, 2R42DK074331-03A2
Yes
University of Louisville
University of Louisville
  • Northwestern University
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • Regenerex, LLC
Principal Investigator: Joseph Leventhal, MD Northwestern Memorial Hospital
University of Louisville
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP